



## Original Article

# Factors Associated with Hospital Admission in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease in a Teaching Hospital

Md. Nure Alom Siddiqui<sup>1</sup>, Shahnaj Sultana<sup>2</sup>, Khan MMR<sup>3</sup>, PM Basak<sup>1</sup>

### Abstract

**Background:** Acute exacerbations of chronic obstructive pulmonary disease (AE-COPD) impair quality of life (QOL), accelerate the decline in lung function and often require hospitalization, and thus, leading to increased healthcare burden. By identifying factors that may be associated with AE-COPD and managing them rationally, not only the hospital admissions could be avoided but progression of the disease may also be slowed.

**Objective.** The aim of the present study was to determine the factors associated with hospital admissions among adults with AE-COPD.

**Methods.** Seventy-three patients admitted with AE-COPD were administered a structured questionnaire during their hospital stay. Data on body mass index (BMI), smoking, symptoms, co-morbidities course of the disease, spirometry management and outcomes during the hospitalisation were obtained. Factors associated with hospital admissions were analyzed.

**Results.** The hospitalization due to AE-COPD was significantly associated with the reduced forced expiratory volume in one second (FEV1), and peak expiratory flow rates, increasing sputum purulence, number of hospitalizations during previous year for COPD and presence of co-morbidities.

**Conclusions.** The study shows that both disease and healthcare-related factors are predictors for hospitalisation. Identification of risk factors and appropriate management may reduce hospitalisation due to AE-COPD.

**Key words:** COPD, Acute exacerbation, Admission, Risk factors.

TAJ 2015; 28: No-2: 52-57

### Introduction

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality worldwide. Exacerbations of COPD are detrimental in progression of the disease and lung function. Exacerbations impair the quality of life (QOL), require frequent hospitalizations and also accelerate the decline of lung function.<sup>1</sup>

Hospitalizations due to exacerbations of COPD account for major economic costs in addition to causing disease progression. The available studies<sup>2,3</sup> have mostly focused on risk factors for admission of stable COPD patients, external factors (e.g., air pollution) and admission,<sup>4</sup> or prognostic factors for hospital mortality.<sup>5-7</sup>

<sup>1</sup> Assistant Professor, Department of Medicine, Rajshahi Medical College, Rajshahi.

<sup>2</sup> Medical Officer (OPD), Department of Skin and VD, Rajshahi Medical College Hospital, Rajshahi.

<sup>3</sup> Associate Professor, Department of Medicine, Rajshahi Medical College, Rajshahi.

The prevention of COPD exacerbations is recognized as an important management goal.<sup>8</sup> By identifying patients who are more likely to have acute exacerbations and treating them in a rational and cost-effective manner, not only the hospital admission could be avoided but also the progression of the disease can be slowed. Observational studies with various designs have evaluated risk factors for hospitalization due to COPD. Independent risk factors reported in these studies include low levels of lung function,<sup>1,2, 9-11</sup> The number of respiratory medications,<sup>11</sup> advancing age,<sup>12</sup> abnormal blood gas levels,<sup>3,9</sup> pulmonary hypertension,<sup>3</sup> low BMI,<sup>3</sup> low levels of physical activity,<sup>9</sup> prior hospital admissions,<sup>2,9,11,12</sup> impaired QOL,<sup>12</sup> current smoking status,<sup>2,13</sup> lack of influenza vaccination,<sup>14</sup> and air pollution.<sup>4</sup> However, no study on risk factors for exacerbations of COPD from Bangladesh is available.

### Material and Methods

The present study was performed in accordance with the Helsinki 1975 15 declaration and the project was undertaken after due ethical clearance. We studied patients admitted with AE-COPD over a period of one year. Patients with COPD were diagnosed as per the criteria of National guidelines asthma and COPD 2010 for the management COPD.<sup>16</sup> According to the guidelines, the AE-COPD is defined as “a sustained worsening of the patient’s condition, from the stable state and beyond normal day-to-day variations, that is acute in onset and necessitates a change in regular medication”.<sup>16</sup>

All the patients in this study were managed as per the hospital protocol of the treating unit. All the patients were administered a structured questionnaire during their hospital stay after they had improved and became stable clinically. The questionnaires were completed by the author himself. Baseline data relating to demographics, respiratory disease history, frequency of admissions to hospital for COPD in the past one year, current respiratory medications and co morbidities was collected. Data on BMI, smoking, symptoms, disease course, other investigations, management and outcome during the

hospitalization were obtained from the patient and in-patient records. Records of previous hospitalizations were also obtained. If a patient was admitted number of times during the study period, the parameters recorded during most recent admission were considered for analysis. Sputum culture for pyogenic organisms and sensitivity were obtained in patients where infective aetiology was suspected. Patients with overlapping features of COPD and asthma were classified as having mixed disease. To address possible diagnostic misclassification, we also performed spirometry in the patients during their hospital stay. Smoking status was recorded as never-smoker, former smoker (left smoking >10 years and left smoking within 10 years), or current smoker. Pack years of smoking were calculated. Symptom frequency between COPD exacerbations was classified into four levels: no symptoms, some symptoms on some days, some symptoms on most days, and symptoms most of the time. Questionnaires that did not have precise information or which had missing values were excluded from the analysis. Only clearly definable and reliably obtained terms were included. Statistical Analysis Candidate variables analysis were: age, sex, BMI calculated as kg/m<sup>2</sup>, FEV<sub>1</sub> as percent predicted, peak expiratory flow rate (PEFR), smoking habits and sputum purulence. The co-morbidities were also assessed as per records. All statistical analyses were carried out using SPSS 16 (Statistical Package for the Social Sciences Inc., USA) software with the help of the statisticians. Data is shown as mean  $\pm$  standard deviation (SD).

### Results

We collected data of 96 admitted patients over one year duration since April 2010 to March 2011. Seventy-three patients met the inclusion criteria for the study. Our sample comprised of 96% males. The demographic baseline characteristics of the patients are shown in table 1. Eighty-eight percent of the admitted patients had current or past smoking habit of ‘Biri’ and 9% were cigarette smokers. Of admitted patients, 46% had at least one co-morbid condition. Mean FEV<sub>1</sub> was 42.5% of the predicted. The medication history during previous month was also obtained and shown in

table 1. In our study, 41 (56%) and 14 (19%) patients were using inhaled and oral corticosteroids, respectively before admission. There were 52 (71%) patients on inhaled  $\beta 2$  - agonists, out of which 18 (25%) were on short-

acting and 34 (47%) were on long acting  $\beta 2$  - agonist, respectively. No association was found between corticosteroid use and the risk of hospitalization due to AE-COPD. Factors for Hospitalizations in AE-COPD

Table 1. Characteristics of the patients with AE-COPD

Male: Female	70:03
Age (years) (mean $\pm$ SD)	60 $\pm$ 9
BMI (kg/m <sup>2</sup> ) (mean $\pm$ SD)	23.0 $\pm$ 5.6
FEV1 (L) (mean $\pm$ SD)	0.96 $\pm$ 0.8
FEV1 % predicted (mean $\pm$ SD)	42.5 $\pm$ 14.0
Smokers (n=73)	71 (97%)
Smoking history in pack years (mean $\pm$ SD)	35 $\pm$ 19
Co-morbidity (n=73)	35 (46%)
History of previous hospitalisation (n=73)	43 (59%)
Medication history (previous one month) Inhaled short acting $\beta 2$ -agonists	18 (25%)
Inhaled anticholinergics	43 (59%)
Inhaled corticosteroids	41 (56%)
Methyl xanthenes	17 (23%)
Inhaled long acting inhaled $\beta 2$ -agonists	34 (47%)
Systemic corticosteroids	14 (19%)

AE-COPD=Acute exacerbations of chronic obstructive pulmonary disease;

BMI=Body mass index; FEV1=Forced expiratory volume in one second

Out of 73 patients, 43 (59%) patients were hospitalised some time earlier for similar illness. The mean time interval between two successive admissions was 5.0 $\pm$ 4.1 months. Fifty-nine percent patients had at least one admission and 37% patients had at least two admissions due to AE-COPD during the last one year. Different types of co-morbidities with which the patients were admitted are shown in table 2. Diabetes and cardiovascular morbidities were more common and were often co-existing with other diseases. those not having this symptom. However, no significant association could be drawn between age, sex and frequency of exacerbations. In addition to the variables, we observed pedal oedema as another possible predictor for hospital admissions.

## Discussion

This study was carried out to determine the factors associated with hospital admission among adults who were admitted with exacerbations of COPD. Our findings revealed that hospitalisations due to

AECOPD were associated with impairment of PEFr and FEV1. The consistent and important association of decreased FEV1 during frequent exacerbations is well known. A low FEV1 is also a pre-eminent risk factor for mortality from COPD

in most epidemiological studies.<sup>3, 17, 18</sup> From the results of the present study, it can be speculated that persistent respiratory infections as reflected in sputum purulence may be facilitating factors for exacerbations. Previous hospitalisation within a year possibly is an important factor that suggests that these patients lack access to routine preventive care required for averting hospitalisations. Ball et al<sup>19</sup> found that co-existent cardiopulmonary disease was a risk factor for hospitalisation. Nearly half of the patients in our study had one or more co morbidities. Fifteen percent patients had cardiovascular related problems and 11% of patients had at least two co-morbidities. Our results also suggest that co-morbidity is a risk factor for frequent exacerbations. Among these, diabetes may be an important risk factor for exacerbations requiring longer periods of hospitalisation associated with aggressive bacterial infection<sup>20</sup> History of pulmonary tuberculosis (PTB) in the past is an important cause of progression of COPD.<sup>21</sup> In India where PTB is endemic and smoking habit is high, the prevalence of COPD with concomitant old tuberculosis (TB) is expected to be more. Further, relapse of TB may mimic AE-COPD clinically. Such observations have also been documented in intensive care settings from south India by Mohan et al.<sup>22</sup> However, we had excluded patients with active PTB from our study. We believe this is the first study from Bangladesh to gather information about predictors of hospitalisation due to AE-COPD. Among other factors, we found sputum purulence as a predictor for exacerbations which may be useful clinically and may be considered in formulating further guidelines. With the growing prevalence of COPD and exacerbations, there is a need for closer follow-up and precise therapeutic and preventive measures to avoid Univariate analysis was performed with initial parameters, the co-morbidities as independent variables and the hospital admissions as dependent variables. Significant variables were then considered for multivariate regression analysis. The variables found as significant factors for hospital admission are shown in table 3. Table 2. Types of co-morbidities and frequency

Co-morbidities	Frequency (%)	Without co-morbidity
Tuberculosis	10(13.7)	38(52.1)
Diabetes	4(5.5)	10(13.7)
Hypertension	4(5.5)	10(13.7)
Diabetes and hypertension	2(2.7)	4(5.5)
Depression	4(5.5)	10(13.7)
Severe pulmonary artery hypertension	1(1.4)	3(4.0)
Diabetes, hypertension and coronary artery diseases	2(2.7)	5(6.7)
Coronary artery diseases	2(2.7)	5(6.7)
HIV positive	1(1.4)	3(4.0)
Diabetes	4(5.5)	10(13.7)
Liver failure	1(1.4)	3(4.0)
Total	73(100)	150(200)

HIV=Human immunodeficiency virus. Multivariate analysis of risk factors for AE-COPD

Variables/Parameters	*P value	*OR	95% *CI
PEFR	0.046	1.835	1.117-3.012
FEV1	0.037	1.365	1.067-3.768
Sputum purulence	0.039	1.731	0.914-3.132
Previous (one year) hospitalisation history	0.048	1.963	1.037-3.814
Co-morbidities	0.041	2.373	1.231-3.127

\*=P is significant if < 0.05, OR=Odds ratio, CI=Confidence interval; PEFR=Peak expiratory flow rate; FEV1 =Forced expiratory volume in one second

The hospitalisation of patients with AE-COPD was significantly associated with the duration of COPD and pre-exacerbation morbidity. The spirometric values (expiratory flow) provide an estimate of the increased risk of exacerbation. A lower FEV1 (percent predicted) was associated with increasing risk of exacerbations. In the present study, 49% had sputum purulence before admission. Patient with persistent purulence in sputum were more likely to have exacerbations than 206 hospital admissions. The risks factors observed in the present study might find a role in decision making in the clinical management of AE-COPD and may reduce frequency of hospitalisations. Our study has some limitations. This is a small observational study. The spirometric data collected during hospital stay may not correlate the pre hospital phase of AE-COPD. The assessment of risk factors were based on patient's previous record and clinical history obtained from the patients. The possible observers' bias and the inaccuracy of the clinical history cannot be ruled out completely. These outcomes, therefore, need to be confirmed by multi centric studies with large sample size.

38(52.1)Tuberculosis 10(13.7) Diabetes and history of tuberculosis 4(5.5)Hypertension 4(5.5)Diabetes and hypertension 2(2.7)Depression 4(5.5)Severe pulmonary artery hypertension 1(1.4)Diabetes, hypertension and coronary arterydiseases 2(2.7)Coronary artery diseases 2(2.7) HIV positive 1(1.4) Diabetes 4(5.5) Liver failure 1(1.4) Total 73(100) HIV=Human immunodeficiency virus. Multivariate analysis of risk factors for AE-COPD

Variables/Parameters	*P value	*OR	95% *CI
PEFR	0.046	1.835	1.117-3.012
FEV1	0.037	1.365	1.067-3.768
Sputum purulence	0.039	1.731	0.914-3.132
Previous (one year) hospitalisation history	0.048	1.963	1.037-3.814
Co-morbidities	0.041	2.373	1.231-3.127

\*=P is significant if < 0.05, OR=Odds ratio, CI=Confidence interval; PEFR=Peak expiratory flow rate; FEV1 =Forced expiratory volume in one second

The hospitalisation of patients with AE-COPD was significantly associated with the duration of COPD and pre-exacerbation morbidity. The spirometric values (expiratory flow) provide an estimate of the increased risk of exacerbation. A lower FEV1 (percent predicted) was associated with increasing risk of exacerbations. In the present study, 49% had sputum purulence before admission. Patient with persistent purulence in sputum were more likely to have exacerbations than 206 hospital admissions. The risks factors observed in the present study might find a role in decision making in the clinical management of AE-COPD and may reduce frequency of hospitalisations. Our study has some limitations. This is a small observational study. The spirometric data collected during hospital stay may not correlate the pre hospital phase of AE-COPD. The assessment of risk factors were based on patient's previous record and clinical history obtained from the patients. The possible observers' bias and the inaccuracy of the clinical history cannot be ruled out completely. These outcomes, therefore, need to be confirmed by multi centric studies with large sample size.

### Conclusion

Retrospective information collected from hospitalized patients with AE-COPD suggests spirometric impairments, frequency of

hospitalisation during the previous year, sputum purulence and co-morbidities are important risk factors for exacerbations necessitating hospitalisation.

### Acknowledgements

We are thankful to the doctors of Medicine Unit I, for their assistance in collecting the data. We are also thankful to both the technicians Jhinuk for their extra efforts for the pulmonary function tests of the patients in this study. We acknowledge the help of Dr ARM Saifuddin Ekram, Professor of Medicine-Rajshahi Medical College and Hospital, Bangladesh.

### References

1. Gudmundsson G, Gislason T, Janson C, Lindberg E, Hallin R, Ulrik CS, et al. Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression. *Eur Respir J* 2005;26:414-9.
2. Garcia-Aymerich J, Monso E, Marrades RM, Escarabill J, Félez MA, Sunyer J, et al. Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. EFRAM study. *Am J Respir Crit Care Med* 2001;164:1002-7.
3. Kessler R, Faller M, Fourgaut G, Menecier B, Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1999;159:158-4.
4. Anderson HR, Spix C, Medina S, Schouten JP, Castellsague J, Rossi G, et al. Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: results from the APHEA project. *Eur Respir J* 1997;10:1064-71.
5. Almagro P, Calbo E, Ochoa de Echaguen A, Barreiro B, Quintana S, Heredia JL, et al. Mortality after hospitalization for COPD. *Chest* 2002;121:1441-8.
6. Connors AF Jr, Dawson NV, Thomas C, Harrell FE Jr, Desbiens N, Fulkerson WJ, et al. Outcomes following acute Factors for Hospitalisation in AE-COPD P.R. Mohapatra and A.K. Janmeja exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). *Am J Respir Crit Care Med* 1996;154:959-67.
7. Fuso L, Incalzi RA, Pistelli R, Muzzolon R, Valente S, Pagliari G, et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. *Am J Med* 1995;98:272-7.
8. Global Initiative for Chronic Obstructive Lung Disease strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: an Asia-Pacific perspective. *Respirology* 2005;10:9-17.
9. Garcia-Aymerich J, Ferrero E, Felez MA, Izquierdo J, Marrades RM, Anto JM. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. *Thorax* 2003;58:100-5.
10. Miravittles M, Guerrero T, Mayordomo C, Sanchez Agudo L, Nicolau F, Segu JL. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis: The EOLO Study Group. *Respiration* 2000;67:495-501.
11. Roberts CM, Lowe D, Bucknall CE, Ryland I, Kelly Y, Pearson MG. Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. *Thorax* 2002;57:137-41.
12. Fan VS, Curtis JR, Tu SP, McDonnell MB, Fihn SD. Using quality of life to predict hospitalization and mortality in patients with obstructive lung diseases. *Chest* 2002;122:429-36.
13. Godtfredsen NS, Vestbo J, Osler M, Prescott E. Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. *Thorax* 2002;57:967-72.
14. Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. *Ann Intern Med* 1999;130:397-403.
15. World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. *JAMA* 1997;277:925-6.
16. Jindal SK, Gupta D, Aggarwal AN. Guidelines for management of chronic obstructive pulmonary disease (COPD) in India: a guide for physicians (2003). *Indian J Chest Dis Allied Sci* 2004;46:137-53.
17. Vilkinan S, Keistinen T, Tuuponen T, Kivela SL. Survival and cause of death among elderly chronic obstructive pulmonary disease patients after first admission to hospital. *Respiration* 1997;64:281-4.
18. Burrows B, Bloom JW, Traver GA, Cline MG. The course and prognosis of different forms of chronic

- airways obstruction in a sample from the general population. *N Engl J Med* 1987;317:1309-14.
19. Ball P, Harris JM, Lawson D, Tillotson G, Wilson R. Acute infective exacerbations of chronic bronchitis. *Q J Med* 1995;88:61-8.
  20. Osman IM, Godden DJ, Friend JA, Legge JS, Douglas JG. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. *Thorax* 1997;52:67-71.
  21. Snider GL, Doctor L, Demas TA, Shaw AR. Obstructive airway disease in patients with treated pulmonary tuberculosis. *Am Rev Respir Dis* 1971;103:625-40.
  22. Mohan A, Premanand R, Reddy LN, Rao MH, Sharma SK, Kamity R, et al. Clinical presentation and predictors of outcome in patients with severe acute exacerbation of chronic obstructive pulmonary disease requiring admission to intensive care unit. *BMC Pulm Med* 2006;6:27.

All corresponds to  
DR. MD. NURE ALOM SIDDIQUI  
Assistant Professor  
Department of Medicine  
Rajshahi Medical College